Key Influencer in the Rare Biomarkers Specimen Collection And Stabilization Market 2025: Increasing Prevalence Of Cancer Is Driving The Growth Of The Rare Bio Markers Specimen Collection And Stabilization Driver

What market dynamics are playing a key role in accelerating the growth of the rare biomarkers specimen collection and stabilization market?
The growing prevalence of cancer is expected to drive the rare biomarker specimen collection and stabilization market. Cancer's increasing prevalence, driven by environmental pollutants, lifestyle factors, and genetics, demands advanced specimen collection and stabilization methods for accurate diagnosis and monitoring. For example, in October 2023, the European Commission reported that new cancer cases in 2022 rose to 2.74 million, a 2.3% increase from 2020. As cancer cases continue to rise, the rare biomarker specimen collection market will expand.

Get Your Rare Biomarkers Specimen Collection And Stabilization Market Report Here:
https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report

How will the growth rate of the rare biomarkers specimen collection and stabilization market shape industry trends by 2034?
The rare biomarkers specimen collection and stabilization market has seen rapid growth in recent years. It is forecast to grow from $32.01 billion in 2024 to $35.4 billion in 2025, at a CAGR of 10.6%. The growth is driven by advancements like the human genome project, increased cancer research, pharmaceutical R&D investments, the growth of genomics and proteomics, and improvements in data management and bioinformatics.

The rare biomarkers specimen collection and stabilization market will reach $52.46 billion by 2029 at a CAGR of 10.3%. Growth factors include the expansion of liquid biopsy applications, consumer demand, the adoption of non-invasive techniques, and biomarker discovery in rare diseases. Trends include preservation technology advancements, genomic and proteomic research growth, point-of-care testing, and AI integration.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp

What trends are poised to drive the future success of the rare biomarkers specimen collection and stabilization market?
Leading companies in the rare biomarker specimen collection and stabilization market are developing cutting-edge solutions like pre-analytical platforms that automate the preparation of plasma and cell samples for multiomic liquid biopsy. These platforms ensure consistent, automated sample handling during blood collection, eliminating the need for special tubes or skilled staff while preserving sample integrity. For example, in May 2022, Tethis S.p.A., an Italy-based biotech firm, launched See.d, a fully automated pre-analytical platform. It features precise sample handling, efficient plasma separation, and the fixation of white blood cells on SmartBioSurface slides, along with a quality control system to evaluate sample stability.

Which primary segments of the rare biomarkers specimen collection and stabilization market are driving growth and industry transformations?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented -

1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users

Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15913

Which geographical regions are pioneering growth in the rare biomarkers specimen collection and stabilization market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the influential players reshaping the rare biomarkers specimen collection and stabilization market landscape?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp

What Is Covered In The Rare Biomarkers Specimen Collection And Stabilization Global Market Report?

•Market Size Forecast: Examine the rare biomarkers specimen collection and stabilization market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the rare biomarkers specimen collection and stabilization market for a structured understanding.
•Key Players Overview: Analyze major players in the rare biomarkers specimen collection and stabilization market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the rare biomarkers specimen collection and stabilization market.
•Segment Contributions: Evaluate how different segments drive overall growth in the rare biomarkers specimen collection and stabilization market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the rare biomarkers specimen collection and stabilization market.
•Industry Challenges: Identify potential risks and obstacles affecting the rare biomarkers specimen collection and stabilization market.
•Competitive Landscape: Review strategic developments in the rare biomarkers specimen collection and stabilization market, including expansions, agreements, and new product launches.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.